SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Arrow Greentech gains on its arm getting approval to manufacture mouth dissolving strips

10 Dec 2018 Evaluate

Arrow Greentech is currently trading at Rs. 85.35, up by 0.80 points or 0.95% from its previous closing of Rs. 84.55 on the BSE.

The scrip opened at Rs. 85.35 and has touched a high and low of Rs. 85.40 and Rs. 83.25 respectively. So far 152 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 568.00 on 09-Jan-2018 and a 52 week low of Rs. 76.40 on 06-Jul-2018.

Last one week high and low of the scrip stood at Rs. 91.85 and Rs. 83.10 respectively. The current market cap of the company is Rs. 100.20 crore.

The promoters holding in the company stood at 65.42%, while Institutions and Non-Institutions held 4.58% and 30.00% respectively.

Arrow Greentech’s wholly owned subsidiary (WOS) company -- Avery Pharmaceuticals, also known as Arrow Rx has received an approval for site plan to manufacture mouth dissolving strips from Food & Drugs Control Administration (FDA). Avery Pharmaceuticals plan to expedite for setting up the manufacturing base near Ahmedabad in the state of Gujarat, to manufacture the patented products like Pharma, Health & Hygiene films.
 
Arrow Greentech (AGTL) is pioneer in manufacturing Water Soluble Film by a unique method using detachable liners. The company’s RND department has many years experience in Coatings, Security Printing, and casting films since many years.

Arrow Greentech Share Price

539.40 -3.45 (-0.64%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Uflex 439.40
EPL 228.95
AGI Greenpac 638.05
Huhtamaki India 184.80
TCPL Packaging 2804.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×